

Resource Summary Report

Generated by RRID on Aug 12, 2026

APC anti-human CD80

RRID:AB_2076147

Type: Antibody

Proper Citation

BioLegend Cat# 305220, RRID:AB_2076147

Antibody Information

URL: http://antibodyregistry.org/AB_2076147

Proper Citation: BioLegend Cat# 305220, RRID:AB_2076147

Target Antigen: CD80

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human CD80

Description: This monoclonal targets CD80

Target Organism: human

Clone ID: Clone 2D10

Antibody ID: AB_2076147

Vendor: BioLegend

Catalog Number: 305220

Alternative Catalog Numbers: 305219

Record Creation Time: 20250819T232926+0000

Record Last Update: 20250820T053030+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-human CD80.

No alerts have been found for APC anti-human CD80.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Kurochkin I, et al. (2026) A combinatorial transcription factor screening platform for immune cell reprogramming. *Cell systems*, 101457.

Apaydin DC, et al. (2026) Lipid nanoparticle-based non-viral in situ gene editing of congenital ichthyosis-causing mutations in human skin models. *Cell stem cell*, 33(2), 233.

Abrey-Recalde MJ, et al. (2026) Combining PD-L1 blockade with a second-generation HSP110 inhibitor enhances antitumor immunity in colorectal cancer. *Cell death & disease*.

Zhou K, et al. (2025) M1-like macrophages regulate T cell infiltration in colorectal cancer through P2X4 receptor. *iScience*, 28(10), 113517.

Liu H, et al. (2024) Lipid imbalance and inflammatory oxylipin cascade at the maternal-fetal interface in recurrent spontaneous abortion. *Heliyon*, 10(24), e40515.

Wenthe J, et al. (2023) Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models. *Journal of translational medicine*, 21(1), 506.

Zhao Y, et al. (2023) cis-B7:CD28 interactions at invaginated synaptic membranes provide CD28 co-stimulation and promote CD8+ T cell function and anti-tumor immunity. *Immunity*.

Fu Y, et al. (2021) CD27-CD38+ B cells accumulated in early HIV infection exhibit transitional profile and promote HIV disease progression. *Cell reports*, 36(2), 109344.

Zhao Y, et al. (2019) PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. *Immunity*, 51(6), 1059.

Waight JD, et al. (2018) Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens. *Cancer cell*, 33(6), 1033.